← All trials
NCT02522013
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2015
- Primary completion
- Oct 1, 2016
- Completion date
- Oct 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 126
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Zhengzhou UniversityLead sponsor
- Jinzhou central hospitalOverall official - principal investigator
- Henan University of Traditional Chinese MedicineOverall official - principal investigator
- Soochow UniversityOverall official - principal investigator
- Zhengzhou UniversityReponsible party - principal investigator
- Hebei UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.